Introduction - GGT is a membrane-bound enzyme that occurs in many parenchymatous organs. Activity of which is found in the kidneys, pancreas, liver, spleen, and small intestine. The serum level of this enzyme is raised only by liver and bile duct disorders. Aim of this study was to estimate the serum level of GGT in patients with cholelithiasis and those with CBD obstruction. METHODS – 28 patients were included in the study, of which 18 were patients with cholelithiasis group 1 and remaining 10 with common bile duct (CBD) obstruction group 2. Patients with liver, renal diseases, chronic alcoholics and on drugs like phenytoin, phenobarbital and oral contraceptives, viral hepatitis, cholecystitis, chronic hepatitis, fatty liver, cholangitis, metastatic carcinoma to the liver, congestive heart failure, chronic alcoholism, post-myocardial infarction, were excluded from the study. RESULTS – The mean serum GGT in group 1 was noted to be 116.67 U/L and that in the group 2 was noted to be 381.50 U/L, Alkaline phosphatase (ALP) levels were noted to be 94 in group 1 and 224.6 in group 2and the difference of the mean value of serum GGT and serum ALP between the 2 groups was statistically significant that is p value <0.05. CONCLUSION - Raised serum GGT along with raised ALP is an accurate diagnostic marker of patients with CBD obstruction.
